


Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy

Tereza Coman,¹ Emmanuel Bachy,² Mauricette Michallet,² Gérard Socié,³ Madalina Uzunov,⁴ Jean Henri Bourhis,⁵ Simona Lapusan,⁶ Alain Brebion,⁷ Stéphane Vigouroux,⁸ Sébastien Maury,⁹ Sylvie François,¹⁰ Anne Huynh,¹¹ Bruno Lioure,¹² Ibrahim Yakoub-Agha,¹³ Olivier Hermine,^{1,14} Noël Milpied,⁸ Mohamad Mohty,^{6,15,16} and Marie Thérèse Rubio^{6,15,16}

¹CNRS UMR, 8147, Hôpital Necker-Enfants Malades, Paris, France; ²CHU Lyon Sud, Pierre Bénite; ³Hôpital St Louis, Paris, France; ⁴Hôpital Pitié Salpêtrière, Paris Cedex 13, France; ⁵Institut Gustave Roussy, Villejuif, France; ⁶Hématologie Clinique et Thérapie Cellulaire, Hopital Saint-Antoine, APHP, Paris, France; ⁷CHU Fort de France, Fort-de-France Cedex; ⁸CHU de Bx-Haut Lévêque University Bordeaux 2, Bordeaux, France; ⁹Centre Hospitalier Henri Mondor, Créteil, France; ¹⁰CHU Angers, Angers, France; ¹¹Hôpital Purpan, Toulouse cedex 9, France; ¹²Hôpital Hautepierre, Strasbourg, France; ¹³CHRU Lille, Lille, France; ¹⁴Service d' Hématologie Adultes, Hôpital Necker-Enfants Malades, Paris, France; ¹⁵Université Pierre et Marie Curie, Paris, France; and ¹⁶INSERM, UMRs 938, Paris, France

©2013 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2012.069328



*according to CTCAE classification (v0.3)

Online Supplementary Figure S1. Adverse events related to lenalidomide.